Journal of Molecular Neuroscience, Год журнала: 2024, Номер 74(4)
Опубликована: Ноя. 8, 2024
Язык: Английский
Journal of Molecular Neuroscience, Год журнала: 2024, Номер 74(4)
Опубликована: Ноя. 8, 2024
Язык: Английский
The International Journal of Biochemistry & Cell Biology, Год журнала: 2024, Номер 173, С. 106614 - 106614
Опубликована: Июнь 28, 2024
Язык: Английский
Процитировано
9Bioresource Technology, Год журнала: 2025, Номер unknown, С. 132372 - 132372
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
1International Immunopharmacology, Год журнала: 2024, Номер 139, С. 112782 - 112782
Опубликована: Июль 28, 2024
Язык: Английский
Процитировано
6Chemico-Biological Interactions, Год журнала: 2024, Номер 400, С. 111166 - 111166
Опубликована: Июль 27, 2024
Smoking is a well-established risk factor for several oral diseases, including cancer, leukoplakia and periodontitis, primarily related to reactive oxygen species (ROS). SS-31, mitochondria-targeting tetrapeptide, has exhibited demonstrable efficacy in medical conditions by attenuating mitochondrial ROS production. However, its potential the treatment of diseases remains underexplored. The aim this study was investigate therapeutic SS-31 mitigating smoking-induced epithelial injury. Through vitro experiments, our results indicate that plays protective role against cigarette smoke extract (CSE) reducing oxidative stress, inflammatory response, restoring function. Furthermore, we found mitophagy, regulated PINK1 (PTEN-induced putative kinase 1)/Parkin (Parkin RBR E3 ubiquitin-protein ligase), critical SS-31. Our findings offer valuable insights into SS-31's CSE-induced dysfunction cells. This provides novel intervention targets smoking-related diseases.
Язык: Английский
Процитировано
3Journal of Molecular Neuroscience, Год журнала: 2024, Номер 74(4)
Опубликована: Ноя. 8, 2024
Язык: Английский
Процитировано
1